Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma
– Data showcase the potential of glofitamab and mosunetuzumab to address diverse patient needs – – Data presented at ASH 2022 and simultaneously published in the New England Journal of Medicine showed that glofitamab, given as a fixed course, induced early and durable responses in people with heavily pretreated large B-cell lymphoma – – 27-month follow-up data showed mosunetuzumab continued to induce high and durable responses in people with relapsed or refractory follicular lymphoma, with 60% experiencing a complete response –
Source: marketscreener.com